Open AccessSulfonylureas and cardiovascular complications of type 2 diabetes mellitus
Author(s) -
Л. В. Недосугова,
Недосугова Людмила Викторовна
Publication year - 2013
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/2072-0351-3753
Subject(s) - glimepiride , medicine , sulfonylurea , type 2 diabetes mellitus , diabetes mellitus , type 2 diabetes , intensive care medicine , endocrinology
This article addresses possible mechanisms for development of cardiovascular events (CVE) in type 2 diabetes mellitus (T2DM) patients treated with sulfonylurea derivatives (SU). Several problems are highlighted in this review, including molecular aspects of pancreatic and extrapancreatic action of these drugs, their comparative potential to induce hypoglycemic events (as predictors of acute CVE) and impairment of ischemic preconditioning, as well as antiarrhythmic activity of certain SU agents. Finally, efficacy and cardiovascular safety of glimepiride in T2DM patients is substantiated based on a survey of current literature.